CHMP Awards Positive Opinion for Myelodysplastic Syndrome Drug
Posted on: Thursday, 30 October 2008, 09:00 CDT
The Aplastic Anemia & MDS International has announced that the European Committee for Medicinal Products for Human Use has awarded Vidaza a positive opinion for the treatment of myelodysplastic syndromes patients who are not eligible for stem cell transplants.
The Committee for Medicinal Products for Human Use's (CHMP's) positive opinion is based on data from the AZA-001 trial, which has demonstrated an overall survival benefit for higher-risk myelodysplastic syndromes (MDS) patients.
The positive opinion will be forwarded to the European Commission that generally follows the recommendation of the CHMP and issues final marketing approval.
John Huber, executive director of the Aplastic Anemia & MDS International Foundation, said: "We are excited by Vidaza's positive CHMP opinion because there are few treatment options for patients in Europe with this disease. Vidaza not only extends patients' lives, but also improves their quality of life. We are hopeful that Vidaza will receive marketing approval shortly and quickly be available for patients across Europe."
Source: Datamonitor
Related Articles
- FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
- Artes Medical Reports Strong Consumer Interest, Rapid Patient Enrollment and Positive Feedback in Largest U.S. Dermal Filler Clinical Study
- Pharmion Presents Clinical Data Demonstrating Significant Survival Advantage of Vidaza(R) in Patients With Myelodysplastic Syndromes (MDS)
- Kosan's Hsp90 Inhibitor, Tanespimycin, Shows Promising Antitumor Activity in Phase 2 Trial of Patients With HER2-Positive Metastatic Breast Cancer
- Interim Phase 2 Aranesp(R) Data Suggest Major Response After 27/28 Weeks of Treatment for Anemia in Patients With Myelodysplastic Syndromes (MDS)
- Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in Anemic Patients With Myelodysplastic Syndrome (MDS); Patients With Bone Marrow Disorder Also Showed Improvements in Hemoglobin Levels and Fatigue
- Macugen Receives Positive Opinion From Europe's CHMP for Treatment of Wet Age-Related Macular Degeneration
- Mortality in Obstructive Sleep Apnea-Hypopnea Patients Treated With Positive Airway Pressure*
- Interim Data Suggest Major Response With Aranesp(R) in Anemic Patients With Myelodysplastic Syndromes (MDS)
- TRISENOX(R) Produces Hematologic Responses in 30 Percent of Patients With Higher-Risk MDS
 |
 |
User Comments (0)
RSS Feeds